SHANGHAI, April 28, 2025 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors.

Abbisko presented the following posters at the 2025 AACR:

Title1: Preclinical Evaluation of ABSK112, a Selective and CNS-penetrant Compound with Strong HER2 Inhibitory Activity for Treating HER2-Driven Solid Tumors

Session Category: Late-Breaking Research: Experimental and Molecular Therapeutics 2

Session Date and Time: April 28, 2025, 2:00 PM – 5:00 PM (CDT)

Location: Poster Section 54

Poster Board Number: 14

Poster Number: LB240

Conclusion:

Our findings establish ABSK112 as a potent, selective and CNS-penetrant HER2 inhibitor, warranting further clinical evaluation of it as a monotherapy or in combination with HER2-targeted ADCs for the treatment of HER2+ cancers with brain metastases.

Title 2: Loss-of-Function (LoF) of KEAP1 promotes cell survival through multiple mechanisms, leading to resistance to KRAS G12C inhibitors

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3

Session Date and Time: April 29, 2025 9: 00AM – 12: 00 PM (CDT)

Location: Poster Section 52

Poster Board Number: 1

Poster Number: LB278

Conclusion:

KEAP1 LoF mutant NSCLCs develop resistance to KRAS G12C inhibitors through reduced drug-induced ROS accumulation, metabolic adaptation, and sustained activation of MAPK and AKT signaling. Combination therapies targeting glutamine metabolism (e.g., GLS1 inhibitors), MAPK (e.g., MEK inhibitors), and PI3K-AKT-mTOR pathways (e.g., BEZ235) reverse resistance and improve therapeutic efficacy in KEAP1-mutant cell lines. These strategies may restore sensitivity to KRAS G12C inhibitors and enhance clinical outcomes.

Title 3: The MTA-Cooperative PRMT5 Inhibitor ABSK131 Exhibits Potent Activity and Broad Synergistic Potential in MTAP-Deleted Cancer Models

Session Category: Late-Breaking Research: Experimental and Molecular Therapeutics 4

Session Date and Time: April 30, 2025 9:00 AM – 12:00 PM (CDT)

Location: Poster Section 51

Poster Board Number: 9

Poster Number: LB427

Conclusion:

ABSK131 exhibits strong anti-tumor activity in MTAP-deleted lung and pancreatic cancer models and synergizes effectively with multiple therapeutic agents. These findings support the continued clinical development of ABSK131 as both a monotherapy and in combination regimens for MTAP-deleted cancers.

Title 4: Discovery and characterization of a highly potent and orally available small-molecule inhibitor for diverse KRAS mutations

Session Category: Late-Breaking Research: Experimental and Molecular Therapeutics 4

Session Date and Time: April 30, 2025 9:00 AM – 12:00 PM (CDT)

Location: Poster Section 51

Poster Board Number: 13

Poster Number: LB431

Conclusion:

Taken together, ABK-KRAS-1 exhibits broad in vitro activity against different KRAS mutations and induces dose-dependent tumor regression in KRAS mutated xenograft models. Moreover, ABK-KRAS-1 possesses favorable drug-like properties. Here, ABK-KRAS-1 is presented as a promising therapeutic candidate for the treatment of cancers harboring KRAS mutations.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

SINGAPORE, April 28, 2025 /PRNewswire/ — Thunes, the Smart Superhighway to move money around the world, is proud to announce the successful raise of its $150 million Series D, the largest in its history, at a substantial valuation increase over its last round. Amid one of the most challenging capital markets environments of recent times, this milestone was achieved in record time.

Thunes proudly welcomes Apis Partners and Vitruvian Partners, two leading private equity firms, both globally recognized for their deep expertise in financial services and emerging markets.

Now profitable and maintaining strong growth momentum, Thunes plans to leverage this capital to supercharge its expansion in the United States, supported by the recent acquisition of licenses across 50 U.S. States, subject to regulatory approval.

These funds will further strengthen Thunes’ Direct Global Network, which today spans 130+ countries, 80+ currencies and 550+ direct integrations, enabling real-time payments across complex and exotic markets.  As cross-border payments swell towards a $150 trillion market opportunity, Thunes stands well positioned to continue to capture a growing share.

Through cutting-edge technology, industry-leading compliance standards, and a seamless customer experience, Thunes continues to make diverse payment systems, including traditional, digital, and emerging currencies, interoperable. With a vision to include the “next billion end users” in emerging markets, Thunes aims to be the go-to solution for fast, secure, and cost-effective cross-border payments, connecting billions of wallets and thousands of partners worldwide.

Floris de Kort, CEO of Thunes, stated, “Thunes’ latest funding round is a clear validation of our strategy and our commitment to sustainable growth. Our performance, marked by a Revenue run-rate of $150 million and positive EBITDA, demonstrates our ability to balance rapid expansion with financial prudence, even in a tumultuous market. This new capital enables us to extend our Direct Global Network, including in the United States, drive technological innovation, from Artificial Intelligence to digital asset ecosystem interoperability, and deliver superior value to the Members of our proprietary Network. In a challenging funding environment, our progress and resilience set a new industry standard.”

Matteo Stefanel, Managing Partner & Co-Founder at Apis Partners, commented, “Thunes has revolutionized global cross-border payments by seamlessly integrating robust technology with a disciplined financial strategy that inspires confidence. The company’s impressive growth record and positive EBITDA performance, even in these unprecedented times, clearly underpin the trust of its Members and their ability to scale effectively. We have been closely monitoring Thunes’ remarkable journey and are consistently impressed by the team’s innovative approach, operational rigor, and strategic foresight. Thunes’ pursuit of excellence redefines industry standards and sets a high bar for reliability and performance in global payments. Lastly, we are especially proud of the work Thunes is doing in accelerating access to affordable financial services across the next billion users in emerging markets, and for Apis to play a small part in continuing this journey.”

Tassilo Arnhold, Partner at Vitruvian Partners, said: “We are proud to partner with the visionary team at Thunes as they build a transformative platform that effectively bridges traditional banking, mobile wallets, and digital assets into one unified solution. At Vitruvian Partners, we value strategic vision, resilience, and commitment to innovation, all of which Thunes exemplifies in every aspect of its operations. They consistently demonstrate the ability to navigate complex market conditions while setting new standards for efficiency and transparency. We are delighted to support Thunes in their mission to continuously set and exceed industry benchmarks, thereby redefining the future of global cross-border payments.”

Thunes’ series D fundraising underscores its financial strength and operational excellence. The company is now set to redefine the standards of global cross-border payments, forging new pathways for growth and innovation in a rapidly evolving fintech landscape.

Proton Partners served as financial advisors on this transaction.

BANGKOK, April 28, 2025 /PRNewswire/ — YeePay, a leading provider of digital payment and enterprise financial solutions, successfully participated in Money20/20 Asia, one of the world’s premier fintech events.

With a focus on “Empowering Tomorrow: Building a Secure, Seamless, and Sustainable Fintech Ecosystem for Asia,” the event brought together over 4,000 senior leaders from banking, payments, fintech, retail, startups, and regulatory sectors to explore the future of financial innovation across the region.

During the event, YeePay engaged with global banks, financial institutions, and technology providers to share its 22 years of enterprise payment expertise and present its intelligent, efficient, and secure end-to-end solutions for cross-border trade. These solutions address complex financial needs such as global collections, payouts, virtual accounts, and FX fund management for enterprises expanding internationally.

“As global trade shifts from single-point direct exports to multi-point re-export models due to geopolitical changes, Chinese enterprises are accelerating their international strategies by establishing overseas factories and trade entities,” said Hua Lei, Senior Vice President and Head of International Business at YeePay.

“However, this new model brings new pain points, including fragmented account management, slow cross-border fund movement, and FX volatility. At YeePay, we integrate our payment infrastructure, deep industry insight, and smart treasury capabilities to deliver a one-stop global transaction network.”

With features such as real-time multi-currency clearing, intelligent FX routing, and multi-level account systems, YeePay empowers businesses with full visibility and control over international funds, supporting long-term growth and global agility.

YeePay continues to advance its dual-engine strategy of internationalization and intelligentization. With 22 years of experience and over 5 million enterprise clients served, its global payment network now spans seven key sectors, including trade and travel. YeePay processes over USD 50 billion in annual cross-border transactions, supports nine major currencies and multiple emerging-market currencies, and enables payouts to over 130 countries and regions, all through a unified transaction processing platform.

As digital transformation and globalization accelerate, YeePay remains committed to strengthening global partnerships and delivering smart, customized solutions to help businesses grow across borders.

About YeePay 

Founded in 2003, YeePay is a leading enterprise payment service provider in China, offering secure, innovative, and intelligent transaction solutions across industries such as airlines & travel, retail, fintech, and cross-border commerce. Focused on financial inclusion and technological advancement, YeePay empowers businesses with seamless digital financial services.

Learn more at: global.yeepay.com 

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR meeting will take place April 25-30, 2025, in Chicago, Illinois.

Dr. Kaijie He, Cancer Biology and ADC Vice President of Innovent, stated: “With continuous advancement of Innovent Academy’s integrated technology platforms, our global R&D capabilities have reached new heights, further strengthening our competitive position in the international biopharmaceutical landscape. This progress has accelerated our ability to design and develop innovative therapeutic candidates with significant global impact. We are proud to showcase a batch of preclinical research findings at this year’s AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs). These scientific advancements highlight our expanding research expertise and underscore our unwavering dedication to creating life-changing treatments for patients across the globe. Moving forward, we remain deeply committed to scientific innovation—advancing target selection precision and pioneering unexplored biological mechanisms—to deliver breakthrough solutions for difficult-to-treat diseases and ensure more patients worldwide can access the benefits of cutting-edge therapeutic technologies. ” 

Research highlights as below:

Late-Breaking Research: Immunology 2
Topic: Preclinical data of IAR037, a novel CD40/PD-L1 bispecific antibody for the treatment of advanced solid tumors resistant to immune checkpoint inhibitors
Abstract Number: LB139
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 52

IAR037 is a novel CD40/PD-L1 bispecific antibody, which simultaneously activates CD40 and blocks PD-1/L1, demonstrating potent anti-tumor efficacy in PD-1-resistant syngeneic mouse models and synergy with PD-1/IL-2^α-bias fusion protein IBI363. Preclinical studies show tumor-specific immune activation with minimal systemic effects and a favorable safety profile in cynomolgus monkeys.

IAR037 presents a novel therapeutic approach for ICI-resistant advanced solid tumors and the IND-enabling study of IAR037 is ongoing.

Late-Breaking Research: Clinical Research 1
Topic: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
Abstract Number: LB222
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 53

IBI3010 is a FRα targeting biparatopic ADC with novel topoisomerase I inhibitor NT1 (DAR8). The biparatopic design enhances tumor binding/internalization.

IBI3010 shows superior cytotoxicity and bystander effect versus mirvetuximab soravtansine (IMGN853) in vitro. IBI3010 demonstrated superior antitumor activity to IMGN853 in FRα-expressing CDX models, particularly in low-FRα expression models. GLP tox studies in cynomolgus monkeys established 60 mg/kg as HNSTD with full tolerability.

These data support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors.

Poster Session: Experimental and Molecular Therapeutics – Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies
Topic: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
Abstract Number: 344
Presentation Form: Poster
Presentation Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 16
Poster Board Number: 11

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell infiltration.

In CDX models with varying TROP2/PD-L1 expression, IBI3014 demonstrated superior cytotoxicity compared to benchmark ADCs, covering broader tumor types. It maintained stability in mice and monkeys, with a well-tolerated HNSTD of 50 mg/kg in monkeys.

IBI3014’s dual mechanism of action not only enhances therapeutic efficacy but also maintains a favorable safety profile, which provides a promising approach for cancer therapy.

Poster Session: Experimental and Molecular Therapeutics – Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies
Topic: Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers
Abstract Number: 345
Presentation Form: Poster
Presentation Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 16
Poster Board Number: 12

IBI3022, a bi-specific ADC targeting Trop2 and B7H4, aims to enhance tumor antigen expression and reduce off-tumor toxicity associated with Trop2 by incorporating a single-arm Trop2 antibody and a less toxic Topoi NT3 linker payload.

In vitro studies demonstrate that IBI3022 exhibits superior cytotoxicity in HT29 cells overexpressing Trop2 and B7H4 compared to mono-specific ADC benchmarks targeting Trop2 or B7H4. In vivo, IBI3022 demonstrates enhanced tumor suppression compared to mono-specific ADC benchmarks in various tumor models with differing levels of Trop2 and B7H4 expression.

IBI3022 represents a promising bi-specific ADC for the treatment of gynecologic cancers, offering improved efficacy and safety profiles.

Poster Session: Experimental and Molecular Therapeutics – Therapeutic Approaches to Attack the Tumor Microenvironment
Topic: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the breaks in immune response and strongly activating T and NK cells in the tumor microenvironment
Abstract Number: 3118
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 24
Poster Board Number: 2

IBI3026 is a bispecific immune agonist targeting PD-1 and IL-12 receptor, designed to improve safety profile by reducing IL-12 activity while enabling tumor-targeted activation through PD-1+ T cell enrichment.

IBI3026 demonstrated potent immune activation (STAT4/IFN-γ signaling) in pre-treated human PBMCs and achieved complete tumor suppression in multiple models (EMT6, CT26, A375, BxPC-3). In cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) of IBI3026 is 150 mg/kg and the calculated therapeutic index is 63.

As a first-in-class candidate, IBI3026 combines PD-1 blockade with localized IL-12 activation, offering a promising strategy for tumors resistant to current immunotherapies.

Poster Session: Immunology – T Cell Engagers
Topic: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy
Abstract Number: 3510
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 38
Poster Board Number: 18

We developed a 2+1 format MUC16 TCE, with improved tumor cell binding affinity, enhanced tumor cell killing potency, and MUC16-dependent T cell binding and activation.

Compared to the benchmark molecule, this MUC16 TCE showed limited T cell binding and activation without MUC16, minimizing off-target activity. This 2+1 format MUC16 TCE also showed a favorable pharmacokinetics profile in mice. Functionally, systemic administration of this MUC16 TCE showed superior anti-tumor efficacy, with undetectable toxicity, in xenograft models.

This innovative TCE shows significant potential for treating MUC16-positive cancers, particularly chemotherapy-resistant ovarian cancer.

Poster Session: Experimental and Molecular Therapeutics – New and Emerging Cancer Drug Targets
Topic: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies
Abstract Number: 4249
Presentation Form: Poster
Presentation Time: Tuesday April 29, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 17
Poster Board Number: 6

IBI3019 is a novel tri-specific antibody targeting EGFR, CDH17, and CD16A for colorectal cancer treatment. It demonstrated strong tumor-specific EGFR inhibition by targeting the overexpressed CDH17 on tumors, while significantly reducing skin toxicities commonly associated with EGFR therapies.

Additionally, IBI3019 incorporates a high-affinity CD16A nanobody that showed better antibody-dependent cell cytotoxicity than those mediated by low-fucose Fc. Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in a pilot tox study. These promising preclinical findings warrant further clinical exploration.

Poster Session: Immunology – Modulation of Tumor Microenvironment: Modulation of Lymphocyte Influx
Topic: A PD1-IFNα fusion protein, with an attenuated IFNα fused to a clinically validated PD1 mAb, elicited PD1-dependent IFNα signaling and superior anti-tumor efficacy
Abstract Number: 4881
Presentation Form: Poster
Presentation Time: Tuesday April 29, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 40
Poster Board Number: 9

We engineered a novel PD1-IFNα fusion protein that combines attenuated IFNα with Sintilimab, inducing potent PD1/PDL1 blockade while eliciting highly PD1-dependent IFNα signaling, selectively activating in PD1-high cells.

Preclinical studies demonstrate superior anti-tumor efficacy compared to PD1 mAb alone in multiple mouse syngeneic tumor models, with undetectable toxicity and a favorable pharmacokinetics profile.

This bi-functional molecule potentially benefits patients with ICB-refractory cancers including pancreatic, ovarian, and MSS colorectal cancers.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.